Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 253

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials

Li, Dandan, Wang, Tiansheng, Shen, Su, Fang, Zhenwei, Dong, Yue, Tang, Huilin·2017·Diabetes, Obesity and Metabolism

Abstract

Aims: To evaluate the effects of different sodium‐glucose co‐transporter 2 ( SGLT2 ) inhibitors on the risk of urinary tract infections ( UTIs ) and genital infections in patients with type 2 diabetes mellitus ( T2DM ). Materials and methods: We systematically searched PubMed , Embase, CENTRAL , and ClinicalTrials.gov from inception to October 9, 2016 to identify randomized controlled trials ( RCTs ) reporting the occurrence of UTIs and genital infections in patients with T2DM treated with SGLT2 inhibitors. Pairwise and network meta‐analyses were performed to calculate odds ratios ( ORs ) and 95% confidence intervals ( CIs ). Meta‐regression was performed to assess explanatory factors that might influence effect size. Results: A total of 52 RCTs involving 36 689 patients were eligible for our meta‐analysis. Canagliflozin, dapagliflozin and empagliflozin were associated with a higher risk of genital infections than placebo, with ORs ranging from 3.21 (95% CI 2.08‐4.93) for dapagliflozin 2.5 mg to 5.23 (95% CI 3.86‐7.09) for canagliflozin 300 mg. Only dapagliflozin 10 mg led to significantly more UTIs than placebo. The increased risk of UTIs and genital infections seemed to have a dose–response relationship for dapagliflozin only. No factors that had a significant modification effect on these infectious events were detected in meta‐regression analysis. Conclusions: The present study found that canagliflozin, dapagliflozin and empagliflozin were associated with a significantly higher risk of genital infections compared with placebo and other active treatments. Only dapagliflozin had a dose–response relationship with UTIs and genital infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12825

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 2

  1. Higgins JPT, 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011)
  2. 10.1111/j.1574-695X.1999.tb01397.x · doi:10.1111/j.1574-695x.1999.tb01397.x · Paper page

Cited by

See all 253

Metadata

Authors
Li, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-12-19
Volume
19
Issue
3
Pages
348-355
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2551376414
Cited by
253
References
53
FWCI
14.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1111/dom.12825
The paper
Li, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H. (2017). Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12825

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.